Filgotinib
CAS 1206161-97-8 2 FDA-DMF suppliersSmall Molecule
Overview
Filgotinib is a potent, selective inhibitor of Janus kinase 1 (JAK1), administered orally for the treatment of moderate-to-severe rheumatoid arthritis. It is designed to preferentially inhibit JAK1, offering a novel therapeutic approach for autoimmune diseases.
Therapeutic areas
RheumatologyGastroenterologyDermatology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.